Patents by Inventor Dipali DESHPANDE
Dipali DESHPANDE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287460Abstract: The present inventions provide mammalian cells that comprise multiple Stable Integration Sites. The inventions provide sites introduced genomically into a Genomic Safe Harbor and introduced genomically outside of that particular Genomic Safe Harbor, including but not limited to another Genomic Safe Harbor. Polynucleotides of interest that encode polypeptides or RNAs of interest can be inserted into the Stable Integration Sites provided according to the inventions. The cells and methods of the inventions can be used for the high yield production of any protein, including viral proteins. Additionally, the cells and methods of the inventions are useful for production of viral vectors, such as AAV, antibodies and other proteins.Type: ApplicationFiled: October 18, 2022Publication date: September 14, 2023Inventors: Michael Goren, Darya Burakov, Gang Chen, Yu Zhao, Dipali Deshpande
-
Publication number: 20210340564Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: July 2, 2021Publication date: November 4, 2021Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Patent number: 11085053Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: GrantFiled: September 10, 2019Date of Patent: August 10, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20210009714Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: ApplicationFiled: September 18, 2020Publication date: January 14, 2021Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
-
Patent number: 10611831Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: May 21, 2019Date of Patent: April 7, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
-
Publication number: 20200063159Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: September 10, 2019Publication date: February 27, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Patent number: 10457959Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: GrantFiled: July 31, 2017Date of Patent: October 29, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20190270800Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: ApplicationFiled: May 21, 2019Publication date: September 5, 2019Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
-
Patent number: 10351622Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: June 16, 2017Date of Patent: July 16, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
-
Patent number: 10227401Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: June 11, 2015Date of Patent: March 12, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
-
Publication number: 20180118852Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: ApplicationFiled: September 11, 2017Publication date: May 3, 2018Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
-
Publication number: 20170335341Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: ApplicationFiled: July 31, 2017Publication date: November 23, 2017Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Publication number: 20170291938Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: ApplicationFiled: June 16, 2017Publication date: October 12, 2017Inventors: Gang CHEN, Darya BURAKOV, Dipali DESHPANDE
-
Patent number: 9758592Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).Type: GrantFiled: November 14, 2013Date of Patent: September 12, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
-
Publication number: 20170241887Abstract: A method of detecting and isolating cells that produce a secreted protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the POI, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a POI wherein such POI is secreted; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.Type: ApplicationFiled: February 27, 2017Publication date: August 24, 2017Inventors: James P. Fandl, Gang Chen, Neil Stahl, George D. Yancopoulos, Dipali Deshpande, Darya Burakov, Thomas Aldrich, Vishal Kamat
-
Patent number: 9732357Abstract: The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems.Type: GrantFiled: August 19, 2015Date of Patent: August 15, 2017Assignee: REGENERON PHARMACEUTICALSInventors: Dipali Deshpande, Darya Burakov, Gang Chen, James Fandl
-
Patent number: 9688751Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: July 1, 2016Date of Patent: June 27, 2017Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
-
Publication number: 20160304598Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: ApplicationFiled: July 1, 2016Publication date: October 20, 2016Inventors: Gang CHEN, Darya BURAKOV, Dipali DESHPANDE
-
Patent number: 9382315Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: November 26, 2014Date of Patent: July 5, 2016Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande
-
Patent number: RE48651Abstract: The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.Type: GrantFiled: April 17, 2019Date of Patent: July 20, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Gang Chen, Darya Burakov, Dipali Deshpande